Cárdenas-Canales Elsa M, Wolfe Lisa L, Tripp Daniel W, Rocke Tonie E, Abbott Rachel C, Miller Michael W
1 Colorado Division of Parks and Wildlife, Wildlife Health Program, Foothills Wildlife Research Facility, 4330 Laporte Ave., Fort Collins, Colorado 80521-2153, USA.
2 US Geological Survey, National Wildlife Health Center, 6006 Schroeder Rd., Madison, Wisconsin 53711, USA.
J Wildl Dis. 2017 Oct;53(4):916-920. doi: 10.7589/2017-02-033. Epub 2017 May 2.
We confirmed safety and immunogenicity of mass-produced vaccine baits carrying an experimental, commercial-source plague vaccine (RCN-F1/V307) expressing Yersinia pestis V and F1 antigens. Forty-five juvenile black-tailed prairie dogs ( Cynomys ludovicianus ) were randomly divided into three treatment groups (n=15 animals/group). Animals in the first group received one standard-dose vaccine bait (5×10 plaque-forming units [pfu]; STD). The second group received a lower-dose bait (1×10 pfu; LOW). In the third group, five animals received two standard-dose baits and 10 were left untreated but in contact. Two vaccine-treated and one untreated prairie dogs died during the study, but laboratory analyses ruled out vaccine involvement. Overall, 17 of 33 (52%; 95% confidence interval for binomial proportion [bCI] 34-69%) prairie dogs receiving vaccine-laden bait showed a positive anti-V antibody response on at least one sampling occasion after bait consumption, and eight (24%; bCI 11-42%) showed sustained antibody responses. The STD and LOW groups did not differ (P≥0.78) in their proportions of overall or sustained antibody responses after vaccine bait consumption. Serum from one of the nine (11%; bCI 0.3-48%) surviving untreated, in-contact prairie dogs also had detectable antibody on one sampling occasion. We did not observe any adverse effects related to oral vaccination.
我们证实了携带表达鼠疫耶尔森菌V抗原和F1抗原的实验性商业来源鼠疫疫苗(RCN-F1/V307)的大规模生产疫苗诱饵的安全性和免疫原性。45只幼年黑尾土拨鼠(草原犬鼠)被随机分为三个治疗组(每组n = 15只动物)。第一组动物接受一剂标准剂量的疫苗诱饵(5×10噬斑形成单位 [pfu];STD)。第二组接受较低剂量的诱饵(1×10 pfu;LOW)。在第三组中,5只动物接受两剂标准剂量的诱饵,10只未接受治疗但处于接触状态。在研究过程中有2只接受疫苗治疗的土拨鼠和1只未治疗的土拨鼠死亡,但实验室分析排除了疫苗的影响。总体而言,在食用含疫苗诱饵后,33只接受疫苗诱饵的土拨鼠中有17只(52%;二项式比例的95%置信区间 [bCI] 34 - 69%)在至少一次采样时显示出抗V抗体阳性反应,8只(24%;bCI 11 - 42%)显示出持续的抗体反应。STD组和LOW组在食用疫苗诱饵后的总体或持续抗体反应比例上没有差异(P≥0.78)。在9只存活的未治疗、处于接触状态的土拨鼠中,有1只(11%;bCI 0.3 - 48%)的血清在一次采样时也检测到了抗体。我们没有观察到与口服疫苗相关的任何不良反应。